Study showing that PolarCap greatly reduces long-term absence after concussion published in the Journal of Neurotrauma

The med-tec company PolarCool AB (publ) announces today that a 5-year clinical study on the effect of acute treatment of concussion with the PolarCap System has been published in the highly regarded Journal of Neurotrauma. The study was conducted by the Division of Neurosurgery, Department of Clinical Science at Lund University.

Results from the study show that treated players returned to play significantly sooner when using PolarCap, as well as show an immediate relief of symptoms. Most interestingly, the study also found that long-term absence (3 weeks or more) was greatly reduced among treated players, by almost 80 percent.

- PolarCool has achieved a very important milestone and the clinical evaluation is a great recognition for our product PolarCap System. The result confirms and strengthens the already strong result from the initial 3-year study and provides further evidence for the effect of the treatment. The fact that the study’s results have now been peer-reviewed and accepted by the highly regarded Journal of Neurotrauma feels fantastic and is a stamp of quality, not only for the study but also the treatment of concussions with PolarCap, says Erik Andersson, CEO of PolarCool

The study is a collaboration between Lund University and the Swedish Hockey League (SHL), and was led by Niklas Marklund, Professor of Neurosurgery at Lund University. The study titled: ‘Shorter recovery time in concussed elite ice hockey players by early head-and-neck cooling - a clinical trial’, is a follow-up study to the original pilot study that was published in Future Medicines journal titled Concussion, 2021. The study compared players with concussion who were treated (cooled) or who received standard concussion treatment. A total of 19 professional hockey teams from the SHL and HockeyAllsvenskan participated in the study.

The results include a total of 132 cases of confirmed concussions, of which 61 were treated with the PolarCap System. The median return to play for treated players was 9 days, compared to 13 days for the control group being highly significant (p<0.001). The proportion of players who did not return to play after 3 weeks was 30 percent among non-treated players, compared to 7 percent among treated players, a difference of almost 80 percent in favor of the treated group.

The Journal of Neurotrauma is a leading journal for reporting on the latest advances in both the clinical and laboratory trials in the field of traumatic brain injury and spinal cord injury. The peer review and acceptance for publication into the Journal of Neurotrauma adds renowned credibility to the study and PolarCap’s effect on treating concussions.

PolarCool CEO Erik Andersson further comments:

- My expectation is that the publication will generate significant exposure and momentum in the sports market. We now look forward to an increased acceptance from the sports medicine community, something that we determined is central to our work in establishing the PolarCap System as a given treatment method for concussion. I also want to especially thank all medical teams that participated in the study for their work. They have played a key part in the acceptance of the study into Journal of Neurotrauma.
The abstract for the study has also been accepted to be shown at the upcoming ‘International Consensus Conference on Concussion in Sport’, which will take place in Amsterdam on the 27th and 28th of October. The conference is held once every four years and is an opportunity for the world’s leading researchers to gather and review the latest research in the field of concussions in sports.

This information is information that PolarCool (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out herein, on October 12th, 2022.

For more information
Erik Andersson – CEO
+46 – 73 860 57 00
E-mail: erik.andersson@polarcool.se

About PolarCool AB (publ)
PolarCool AB (publ) is a medical device company that develops, markets, and sells products for sports medicine. The company focuses on treatment of concussive and sub-concussive brain injury with the portable cooling device PolarCap® System. PolarCool AB (publ) is based in Lund, Sweden, and its shares are listed on Spotlight Stock Market.